Willington Ku, MD
Ophthalmology · Lewisville, TXNPI 1518975523
Payments from drug & device makers
Across 232 payments — averaging $32.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$1K
- Bausch & Lomb Americas Inc.$844
- Alcon$797
- Bausch & Lomb, A Division Of Bausch Health US, LLC$625
- Rxsight Inc$474
- plus $2K from 16 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$7,32998%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 33 | $1,657 |
| AbbVie(2 entities) | 57 | $1,231 |
| Bausch & Lomb Americas Inc. | 25 | $844 |
| Alcon | 43 | $797 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $625 |
| Rxsight Inc | 7 | $474 |
| Glaukos Corporation | 8 | $455 |
| Carl Zeiss Meditec USA, Inc. | 6 | $417 |
| Novartis | 12 | $226 |
| Aerie Pharmaceuticals, Inc. | 6 | $222 |
| Ivantis, Inc | 1 | $150 |
| Sun Pharmaceutical Industries Inc. | 5 | $103 |
| Sight Sciences, Inc. | 4 | $67 |
| Biotissue Holdings Inc. | 3 | $64 |
| Dompe US, Inc. | 1 | $29 |
| Ziemer USA | 1 | $26 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Thea Pharma Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Tearlab Corp | 1 | $19 |
| Harrow Eye, LLC | 1 | $16 |
| NEW World Medical,inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$284
- CATALYS SYSTEM$264
- RXSIGHT CONTACT LENS$250
- RXSIGHT INJECTOR CARTRIDGE$250
- RXSIGHT INJECTOR HANDPIECE$250
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$250
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$250
- iDoseTR$230
- VERACITY SURGICAL$204
- Hydrus$150
- AcrySof IQ PanOptix UV IOL$136
- AcrySof IQ VIVITY$136
- AcrySof$130
- Tecnis IOL$130
- LOTEMAX SM$123
- ARGOS$122
- Rocklatan$122
- Rhopressa$122
- ENVISTA ENVY IOL$121
- Catalys Laser System$120
How this compares
$7,498 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 176 | $102,723 |
| CombiganBrimonidine Tartrate/Timolol | 81 | $37,867 |
| XiidraLifitegrast | 44 | $34,354 |
| RestasisCyclosporine | 22 | $25,077 |
| Travoprost | 122 | $21,204 |
| RhopressaNetarsudil Mesylate | 41 | $18,302 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 103 | $18,109 |
| ProlensaBromfenac Sodium | 49 | $16,619 |
| Lotemax SmLoteprednol Etabonate | 54 | $13,493 |
| VyzultaLatanoprostene Bunod | 29 | $11,776 |
| Latanoprost | 922 | $10,567 |
| BesivanceBesifloxacin Hcl | 42 | $9,187 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $9,035 |
| Timolol Maleate | 314 | $7,856 |
| Alphagan PBrimonidine Tartrate | 11 | $5,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,231 | $170,819290 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $844 | $46,13073 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance | $625 | $39,298145 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $222 | $18,30241 claims |
| AlconSimbrinza | $797 | $9,03539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Lewisville
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.